Atlas Trials

Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

Clinical trial NCT05512416 · UNKNOWN

Trial details

NCT number
NCT05512416
Sponsor
The Affiliated Hospital of Qingdao University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2022-08-01
Primary completion
2023-08-01
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.